Association of CD274 (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung Cancer

We sought to characterize response to immune checkpoint inhibitor (ICI) in non-squamous non-small cell lung cancer (NSCLC) across various CD274 copy number gain and loss thresholds and identify an optimal cutoff. A de-identified nationwide (US) real-world clinico-genomic database was leveraged to st...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The oncologist (Dayton, Ohio) Ohio), 2022-09, Vol.27 (9), p.732-739
Hauptverfasser:	Murugesan, Karthikeyan, Jin, Dexter X, Comment, Leah A, Fabrizio, David, Hegde, Priti S, Elvin, Julia A, Alexander, Brian, Levy, Mia A, Frampton, Garrett M, Montesion, Meagan, Roychowdhury, Sameek, Kurzrock, Razelle, Ross, Jeffrey S, Albacker, Lee A, Huang, Richard S P
Format:	Artikel
Sprache:	eng
Schlagworte:	Cancer Diagnostics and Molecular Pathology Copy number variations Diagnosis Drug therapy Health aspects Influence Lung cancer, Non-small cell
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!